Brief: Seelos Therapeutics Announces Completion Of Open-Label Patient Enrollment Of Proof Of Concept Study Of SLS-002
05/03/2021 14:12
March 5 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS ANNOUNCES COMPLETION OF OPEN-LABEL
PATIENT
ENROLLMENT OF PROOF OF CONCEPT STUDY OF SLS-002 (INTRANASAL
RACEMIC KETAMINE) FOR ACUTE SUICIDAL IDEATION AND BEHAVIOR IN
PATIENTS WITH MAJOR DEPRESSIVE DISORDER
Source text for Eikon: ID:nPn3Vbvbma
Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio